Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 43

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 43
---
ificia Universidad Javeriana.

<div align='center'>27</div>

COMPE NSATION DISCUSSION AND ANALYSIS This compensation discussion and analysis provides information about the material components of our executive compensation program for our “named executive officers” for 2024, consisting of the following persons:

| Name                      |     | Position                                        |
| R. Scott Struthers, Ph.D. |     | President, Chief Executive Officer and Director |
| Marc Wilson (1)           |     | Former Chief Financial Officer                  |
| Stephen Betz, Ph.D.       |     | Chief Scientific Officer                        |
| Dana Pizzuti, M.D.        |     | Chief Medical and Development Officer           |
| Jeff Knight               |     | Chief Operating Officer                         |

(1) As previously disclosed on the Current Reports on Form 8-K filed by the Company on August 8, 2024, February 24, 2025 and April 4, 2025, Mr. Wilson ceased serving as the Chief Financial Officer of the Company, effective February 28, 2025, after which he remained with the Company as an employee to assist with the transition of his duties to the Company’s current Chief Financial Officer, Tobin “Toby” Schilke, through April 1, 2025. Mr. Wilson departed for personal reasons, not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Specifically, this compensation discussion and analysis provides an overview of our executive compensation philosophy, the overall objectives of our executive compensation program, and each compensation component that we provide. In addition, we explain how and why the compensation committee and our board of directors arrived at specific compensation policies and decisions involving our named executive officers during the fiscal year ended December 31, 2024. EXECUTIVE SUMMARY Company Overview Crinetics is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Endocrine pathways function to maintain homeostasis and commonly use peptide hormones acting through G protein coupled receptors, or GPCRs, to regulate many aspects of physiology, including growth, energy, metabolism, gastrointestinal function and stress responses. We have built a highly productive drug discovery and development organization with extensive expertise in endocrine GPCRs. We have discovered a pipeline of oral nonpeptide (small molecule) new chemical entities that target peptide GPCRs to treat a variety of endocrine diseases where treatment options